EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

03 March 2014
EMA/PRAC/127750/2014
Pharmacovigilance Risk Assessment Committee (PRAC)

Pharmacovigilance Risk Assessment Committee (PRAC)

Draft agenda for the meeting on 3-6 March 2014

Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures
(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0

Signals assessment and prioritisation
(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks.
The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.
The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)
(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.
RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)
(Item 6 of the PRAC agenda)

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7051
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation.
PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)
(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections
(Item 8 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

Chair: June Raine – Vice-Chair: Almath Spooner

3 March 2014, 13:00 – 19:00, room 3/A

4 March 2014, 08:30 – 19:00, room 3/A

5 March 2014, 08:30– 19:00, room 3/A

6 March 2014, 08:30 – 16:00, room 3/A

Organisational, regulatory and methodological matters (ORGAM)

20 March 2014, 10:00-12:00, room 2/E, via teleconference

Health and Safety Information

In accordance with the Agency's Health and Safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regards to therapeutic indications listed against products it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised and start of referrals will also be available. For orphan medicinal products, the product name and the applicant are published as this information is already publicly available.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents under Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

1.2. Adoption of agenda of the meeting of 3-6 March 2014

Status: *for adoption*

Document: PRAC Agenda Rev.3 due for publication on 3 March 2014

1.3. Minutes of the previous PRAC meeting on 3-6 February 2014

Status: *for adoption*

Document: PRAC final Minutes due for publication by 14 March 2014

2. EU Referral Procedures for Safety Reasons: Urgent EU Procedures

2.1. Newly triggered procedures

None

2.2. Ongoing Procedures

None

2.3. Procedures for finalisation

None

2.4. Planned public hearings

None

3. EU Referral Procedures for Safety Reasons: Other EU Referral Procedures

3.1. Newly triggered Procedures

None

3.2. Ongoing Procedures

3.2.1. Agents acting on the renin-angiotensin system (CAP, NAP):
angiotensin receptor blockers (**ARBs**), **angiotensin converting enzyme inhibitors** (**ACEi**), **direct renin inhibitors** (**aliskiren**)

- Review of the risks of dual blockade of the renin angiotensin system through concomitant use of ARBs, ACEi or aliskiren-containing medicines following the notification by Italy of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Carmela Macchiarulo (IT)
PRAC Co-Rapporteurs: Margarida Guimarães (PT), Valerie Strassmann (DE), Tatiana Magálová (SK), Dolores Montero Corominas (ES), Almath Spooner (IE), Menno van der Elst (NL), Julie Williams (UK), Qun-Ying Yue (SE)

Administrative details:
Procedure number: EMEA/H/A-31/1370
EPITT 13359 – Follow up January 2014
PRAC Co-Rapporteurs (responsibility per substance): Margarida Guimarães (PT) (lisinopril); Carmela Macchiarulo (IT) (delapril, telmisartan, aliskiren, moexipril); Tatiana Magálová (SK) (spirapril, quinapril); Dolores Montero Corominas (ES) (fosinopril, irbesartan); Almath Spooner (IE) (benazepril, cilazapril, perindopril); Valerie Strassmann (DE) (ramipril, eprosartan, olmesartan); Menno van der Elst (NL) (trandolapril, losartan, azilsartan); Julie Williams (UK) (captopril, imidapril, zofenopril, candesartan); Qun-Ying Yue (SE) (enalapril, valsartan)
MAH(s): Actavis (Telmisartan Actavis, Actelsar HCT), Bayer Smith Kline Beecham (Kinzalmono, Kinzalkomb, Pritor, Pritor Plus), Boehringer Ingelheim (Micardis, Micardis Plus, Onduarp, Twynsta), Krka (Ifirmasta, Ifirmacombi, Tolura), Novartis (Copalia, Copalia HCT, Exforge, Exforge HCT, Dafiro, Dafiro HCT, Imprida), Novartis Europharm Ltd (Rasilamlo, Rasilez, Rasilez HCT, Rasitrio), Pharmathen S.A. (Sabervel), Sanofi-Winthrop / BMS (Aprovel, CoAprovel, Irbesartan Zentiva, Irbesartan HCT Zentiva, Karvea, Karvezide), Takeda (Edarbi, Ipreziv), Teva Pharma / Pharmachemie (Irbesartan Teva, Irbesartan HCT Teva, Telmisartan Teva, Telmisartan Teva Pharma), various
Scientific Advisory Group on Cardiovascular Issues (SAG CVS): Report from the Chair (Maarten Simoons) of the meeting held on 11 February 2014
Documents:
For adoption: Second list of outstanding issues (LoOI) and revised timetable

3.2.2. **Bromocriptine** (NAP)

- Review of the benefit-risk balance following notification by France of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)
PRAC Co-Rapporteur: Isabelle Robine (FR)

Administrative details:
Procedure number: EMEA/H/A-31/1379
MAH(s): Sanofi-aventis, Meda Pharma, various
Documents:
For adoption: List of outstanding issues (LoOI) and revised timetable

3.3. Procedures for finalisation

3.3.1. **Domperidone** (NAP)

- Review of the benefit-risk balance following notification by Belgium of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

Status: *for discussion and adoption of recommendation to CMDh*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)
PRAC Co-Rapporteur: Jean-Michel Dogné (BE)

Administrative details:
Procedure number: EMEA/H/A-31/1365
EPITT 15994 – Follow up January 2014
MAH(s): Janssen-Cilag, various
Oral Explanation(s): Janssen-Cilag
Documents:
For adoption: PRAC AR, PRAC recommendation

3.3.2. **Zolpidem** (NAP)

- Review of the benefit-risk balance following notification by Italy of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

Status*: for discussion and adoption of recommendation to CMDh*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)
PRAC Co-Rapporteur: Jelena Ivanovic (IT)

Administrative details:
Procedure number: EMEA/H/A-31/1377
EPITT 17427 – Follow up December 2013
MAH(s): Sanofi-aventis, various
Documents:
For adoption: PRAC AR, PRAC recommendation

3.4. Re-examination procedures

3.4.1. **Diacerein** (NAP)

- Re-examination procedure of the PRAC recommendation following the review of the benefit-risk balance following notification by France of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

Status: *for discussion and adoption of recommendation to CMDh*

Regulatory details:
PRAC Rapporteur: Margarida Guimarães (PT)
PRAC Co-Rapporteur: Harald Herkner (AT)

Administrative details:
Procedure number: EMEA/H/A-31/1349
EPITT 15994 – Follow-up December 2013
MAH(s): Negma-Wockhardt, TRB Chemedica
Oral Explanation(s): Negma-Wockhardt, TRB Chemedica
Documents:
For adoption: PRAC AR, PRAC recommendation

3.5. Article 5(3) of Regulation (EC) No 726/2004 as amended: PRAC advice on CHMP request

None

4. Signals assessment and prioritisation1

4.1. New signals detected from EU spontaneous reporting systems

4.1.1. **Cefepime** (NAP)

- Signal of convulsions

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: *to be appointed*

Administrative details:
EPITT 17859 – New signal
MAH(s): various
Lead MS: PT
Documents:
For adoption: PRAC recommendation

4.1.2. **Cefepime** (NAP)

- Signal of drug reaction with eosinophilia and systemic symptoms (DRESS)

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: *to be appointed*

Administrative details:
EPITT 17866 – New signal
MAH(s): various
Lead MS: PT
Documents:
For adoption: PRAC recommendation

4.1.3. **Regorafenib – STIVARGA** (CAP)

- Signal of hypersensitivity, drug reaction with eosinophilia and systemic symptoms (DRESS)

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
EPITT 17813 – New signal
MAH(s): Bayer Pharma AG
Lead MS: NL
Documents:
For adoption: PRAC recommendation

[1] Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required

4.1.4. Tacrolimus - **ADVAGRAF** (CAP), **MODIGRAF** (CAP), NAP
Febuxostat – **ADENURIC** (CAP)

- Signal of potential drug-drug interaction between systemic tacrolimus and febuxostat

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Almath Spooner (IE)

Administrative details:
EPITT 17809 – New signal
MAH(s): Astellas Pharma Europe B.V. (Advagraf, Modigraf), Menarini International Operations Luxembourg S.A. (Adenuric), various

4.2. New signals detected from other sources

4.2.1. **Testosterone** (NAP)

- Signal of cardiovascular and thrombotic risks

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: *to be appointed*

Administrative details:
EPITT 17877 – New signal
MAH(s): various
Lead MS: EE
Documents:
For adoption: PRAC recommendation

4.3. Signals follow-up and prioritisation

4.3.1. **Bupropion** (NAP)

- Signal of pancytopenia

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure scope: Evaluation of the MAH's responses to PRAC recommendation as adopted at PRAC in November 2013
EPITT 17727 - Follow-up November 2013
MAH(s): GlaxoSmithKline, various
Documents:
For adoption: PRAC recommendation

4.3.2. **Goserelin** (NAP)

- Signal of long duration flushing and hyperhidrosis

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure scope: Evaluation of the MAH's responses to PRAC recommendation as adopted at PRAC in November 2013
EPITT 17698 - Follow-up November 2013
MAH(s): Astra Zeneca, various
Documents:
For adoption: PRAC recommendation

4.3.3. Quetiapine (NAP)

- Signal of suicidality in major depressive disorder (MDD) patients

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure scope: Evaluation of the MAH's responses to PRAC recommendation as adopted at PRAC in October 2013
EPITT 17709 - Follow-up October 2013
MAH(s): various
Documents:
For adoption: PRAC recommendation

4.3.4. Tenofovir disoproxil fumarate – VIREAD (CAP)
efavirenz, emtricitabine, tenofovir disoproxil fumarate - ATRIPLA (CAP)
emtricitabine, rilpivirine, tenofovir disoproxil fumarate – EVIPLERA (CAP)
elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate - STRIBILD (CAP)
emtricitabine, tenofovir disoproxil fumarate - TRUVADA (CAP)
Diclofenac (NAP)

- Signal of acute kidney injury caused by co-administration of tenofovir disoproxil fumarate and diclofenac (Publication from Bickel M et al, HIV Medicine 2013)

Status: *for discussion*

Regulatory details:
PRAC Rapporteur (overall): Isabelle Robine (FR)

Administrative details:
Procedure scope: Evaluation of the MAH's responses to the PRAC recommendation adopted at PRAC in January 2014
EPITT 17777 - Follow-up January 2014
MAH(s): Gilead Sciences International Ltd (Eviplera, Stribild, Truvada, Viread), Bristol-Myers Squibb and Gilead Sciences Ltd. (Atripla), various
Documents:
For adoption: PRAC recommendation

5. Risk Management Plans

5.1. Medicines in the pre-authorisation phase

5.1.1. Aclidinium, formoterol fumarate

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003745, EMEA/H/C/003969
Intended indication: Maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD)
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.2. Bazedoxifene, oestrogens conjugated

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002314
Intended indication: Treatment of oestrogen deficiency and osteoporosis
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.3. Dolutegravir, abacavir, lamivudine

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status*: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002754
Intended indication: Treatment of human immunodeficiency virus (HIV) infection in adults and adolescents from 12 years of age who are antiretroviral treatment-naïve or are infected with HIV without documented or clinically suspected resistance to dolutegravir, abacavir, lamivudine
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.4. Empagliflozin

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status*: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002677
Intended indication: Treatment of type 2 diabetes mellitus
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.5. Faldaprevir

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

***Status**: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003720
Intended indication: Treatment of chronic genotype-1 hepatitis C virus (HCV) infection
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.6. Human fibrinogen, human thrombin

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

***Status**: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002807
Intended indication: Adjunct to haemostasis
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.7. Ibrutinib

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:

Administrative details:
Product number(s): EMEA/H/C/003791
Intended indication: Treatment of mantle cell lymphoma, chronic lymphocytic leukaemia, small lymphocytic lymphoma
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.8. Idelalisib

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

***Status**: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003843
Intended indication: Treatment of patients with relapsed chronic lymphocytic leukaemia (CLL) and refractory indolent non-Hodgkin lymphoma (iNHL)
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.9. Insulin degludec, liraglutide

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

***Status**: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002647
Intended indication: Treatment of type 2 diabetes mellitus
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.10. Insulin glargine

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

***Status**: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002835, *Biosimilar*
Intended indication: Treatment of diabetes mellitus
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.11. Mifepristone

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

***Status**: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002830
Intended indication: Treatment of signs and symptoms of endogenous Cushing's syndrome in adults
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.12. Nonacog gamma

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

***Status**: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003771
Intended indication: Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency)
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.13. Ospemifene

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

***Status**: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002780
Intended indication: Treatment of vulvar and vaginal atrophy (VVA)
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.14. Peginterferon beta-1a

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

***Status**: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002827
Intended indication: Treatment of relapsing multiple sclerosis
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.15. Perflubutane

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002347
Intended indication: Detection of coronary artery disease (CAD)
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.16. Secukinumab

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status*: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003729
Intended indication: Treatment of plaque psoriasis
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.17. Simeprevir

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status*: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002777
Intended indication: Treatment of chronic hepatitis C (CHC) genotype 1 or genotype 4 infection
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.18. Simoctocog alfa

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status*: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002813
Intended indication: Treatment and prophylaxis of bleeding
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.19. Siltuximab – SYLVANT (CAP MAA)

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status*: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/003708, *Orphan*
Intended indication: Treatment of multicentric Castleman's disease (MCD)
Applicant: Janssen-Cilag International NV
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.20. Tacrolimus

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

***Status**: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002655*, Hybrid*
Intended indication: Prophylaxis of transplant rejection in adult kidney allograft recipients
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.21. Tobramycin

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

***Status**: for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002633*, Hybrid*
Intended indication: Treatment of chronic pulmonary infection
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.1.22. Trametinib

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

***Status:** for discussion and agreement of advice to CHMP*

Administrative details:
Product number(s): EMEA/H/C/002643
Intended indication: Treatment of unresectable or metastatic melanoma with a BRAF V600 mutation
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.2. Medicines already authorised

RMP in the context of a variation[2] – PRAC-led procedure

5.2.1. Dabigatran – PRADAXA (CAP)

- Evaluation of an RMP in the context of a variation

***Status**: for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Doris Stenver (DK)

Administrative details:
Procedure number(s): EMEA/H/C/000829/II/0058
Procedure scope: Changes in the agreed study protocol for 1160.136 (SPAF MEA 025), a global registry program GLORIA-AF investigating patients with newly diagnosed non-valvular AF at risk for stroke receiving dabigatran
MAH(s): Boehringer Ingelheim International GmbH
Documents:
For adoption: PRAC AR

[2] In line with the revised variation regulation for submissions as of 4 August 2013

5.2.2. Human fibrinogen, human thrombin – EVICEL (CAP)

- Evaluation of an RMP in the context of a variation

***Status**: for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

Administrative details:
Procedure number(s): EMEA/H/C/000898/II/0026
Procedure scope: Update of the RMP version 11
MAH(s): Omrix Biopharmaceuticals N. V.
Documents:
For adoption: PRAC AR

5.2.3. Insulin glulisine – APIDRA (CAP)

- Evaluation of an RMP in the context of a variation

***Status**: for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000557/II/0054
Procedure scope: Update of the RMP version 6.0
MAH(s): Sanofi-aventis Deutschland
Documents:
For adoption: PRAC AR

5.2.4. Prucalopride – RESOLOR (CAP)

- Evaluation of an RMP in the context of a variation

***Status**: for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/001012/II/0030
Procedure scope: Update of the RMP version 11 and updated study protocol for a study specified in the Pharmacovigilance plan, following a request from the PRAC based on the review of the last PSUR 006 (EMEA/H/C/001012/PSU/012) and RMP vs. 10 (EMEA/H/C/1012 RMP 020)
MAH(s): Shire Pharmaceuticals Ireland Ltd.
Documents:
For adoption: PRAC AR

5.2.5. Tegafur, gimeracil, oteracil – TEYSUNO (CAP)

- Evaluation of an RMP in the context of a variation

***Status**: for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/001242/II/0016
Procedure scope: Update of the RMP version 5.1 to modify the post-authorisation phase III clinical study to assess efficacy and safety of Teysuno versus an appropriate triplet comparator in the RMP (MEA 001). In addition the MAH took the opportunity to update the RMP with a new amendment for phase I study TPU-S1119 (MEA 002)
MAH(s): Nordic Group B.V.
Documents:
For adoption: PRAC AR

RMP in the context of a variation – CHMP-led

5.2.6. Abiraterone – ZYTIGA (CAP)

- Evaluation of an RMP in the context of a variation

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

Administrative details:
Procedure number(s): EMEA/H/C/002321/II/0018/G
Procedure scope: Update of SmPC section 4.5 with information regarding OATP1B1 and CYP2C8 inhibition by abiraterone based on the results of drug-drug interaction studies FK10383 and 212082PCR1011 included in the RMP
MAH(s): Janssen-Cilag International
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.2.7. Adefovir dipivoxil – HEPSERA (CAP)

- Evaluation of an RMP in the context of a variation

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

Administrative details:
Procedure number(s): EMEA/H/C/000485/II/0064
Procedure scope: Update of SmPC section 4.4 on the risk for renal impairment and appropriate monitoring of renal function
MAH(s): Gilead Sciences International
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.2.8. Amifampridine – FIRDAPSE (CAP)

- Evaluation of an RMP in the context of a variation

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/001032/II/0026, *Orphan*
Procedure scope: Update of the SmPC based on data from a completed QTc study (specific obligation): section 4.4 to add a statement providing information on ECG morphological changes, section 4.8 to

include additional terms with > 10% incidence (hypoaesthasia, paraesthesia, hyperhidrosis and cold sweat) and section 4.9 to reflect the experience with higher doses tested. In parallel, the MAH proposed to reflect results from the QTc study in section 5.1 of the SmPC. The MAH also proposed to update Annex II to delete reference to the respective specific obligation (SOB 001)
MAH(s): BioMarin Europe Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.2.9. Anidulafungin – ECALTA (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/000788/II/0026
Procedure scope: Update of SmPC sections 4.1, 4.4, 4.8 and 5.1 following the CHMP assessment of efficacy and safety data of Ecalta in neutropenic patients with invasive candidiasis and non-neutropenic patients with Cancida deep tissue infection (MEA 014.3)
MAH(s): Pfizer Limited
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.2.10. Belimumab – BENLYSTA (CAP)

- Evaluation of an RMP in the context of a variation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002015/II/0023
Procedure scope: Update of SmPC section 4.4 to add a warning regarding progressive multifocal leukoencephalopathy (PML)
MAH(s): Glaxo Group Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.2.11. Ceftaroline fosamil – ZINFORO (CAP)

- Evaluation of an RMP in the context of a variation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002252/II/0008
Procedure scope: Evaluation of final results of a single-dose PK study of ceftaroline fosamil in children from birth to less than 12 years of age with suspected or confirmed infection (study P903-201/D3720C00006)
MAH(s): AstraZeneca AB
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.2.12. Eslicarbazepine – ZEBINIX (CAP)

- Evaluation of an RMP in the context of a variation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

Administrative details:
Procedure number(s): EMEA/H/C/000988/II/0035
Procedure scope: Update of SmPC sections 4.4 and 4.8 to update the safety information based on a cumulative safety analyses of the available clinical data including the results of a phase III study in the approved indication
MAH(s): Bial - Portela & Cª, S.A.
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.2.13. Exenatide – BYDUREON (CAP)

- Evaluation of an RMP in the context of a variation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002020/II/0017/G
MAH(s): Bristol-Myers Squibb/AstraZeneca EEIG
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.2.14. Golimumab – SIMPONI (CAP)

- Evaluation of an RMP in the context of a variation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/000992/II/0055
Procedure scope: Update of SmPC sections 4.8 and 5.1 to reflect the safety and efficacy data (week 256 for efficacy and week 268 for safety) for studies C0524T05, C0524T06, C0524T11, C0524T08, and C0524T09
MAH(s): Janssen Biologics B.V.
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.2.15. Human fibrogen, human thrombin – EVARREST (CAP)

- Evaluation of an RMP in the context of a variation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

Administrative details:
Procedure number(s): EMEA/H/C/002515/II/0002/G
MAH(s): Omrix Biopharmaceuticals N. V.
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.2.16. Iloprost – VENTAVIS (CAP)

- Evaluation of an RMP in the context of a variation, line extension

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

Administrative details:
Procedure number(s): EMEA/H/C/000474/X/0043
Procedure scope: Addition of a new strength: 20 microgram/ml nebuliser solution (in 30 and 168 ampoules package sizes)
MAH(s): Bayer Pharma AG
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.2.17. Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted) – PANDEMRIX (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000832/II/0069
Procedure scope: Restriction of the indication to adults of 18 years of age and older in an officially declared pandemic situation caused by A (H1N1)v 2009 virus and to update SmPC sections 4.2, 4.4, 4.8 and 5.1 to reflect the totality of data on the risk of narcolepsy and an updated benefit-risk assessment of Pandemrix, based on the data currently available to the MAH on H1N1 influenza disease burden, effectiveness and safety of Pandemrix and available epidemiology data on narcolepsy
MAH(s): GlaxoSmithKline Biologicals
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

See also under 10.1.2.

5.2.18. Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) – FOCLIVIA (CAP)

- Evaluation of an RMP in the context of a variation

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Carmela Macchiarulo (IT)

Administrative details:
Procedure number(s): EMEA/H/C/001208/II/0008/G
Procedure scope: Grouping of three type II variations, whereby the MAH proposes 1) update of SmPC sections 4.2, 4.8 and 5.1 with immunogenicity and safety from study V111_03 in children; 2) update

of SmPC section 4.4 with data on convulsion; 3) update of SmPC sections 4.3 and 4.4 to include barium sulphate among the trace residues and an update of SmPC section 4.8 based on a cumulative review on thrombocytophenia
MAH(s): Novartis Vaccines and Diagnostics S.r.l.
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.2.19. Pasireotide – SIGNIFOR (CAP)

- Evaluation of an RMP in the context of a variation, line extension

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002052/X/0010
Procedure scope: Line extension application to add 20mg, 40mg and 60mg powder and solvent for suspension for injection in the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative, or who are inadequately controlled on treatment with other somatostatin analogues
MAH(s): Novartis Europharm Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.2.20. Ponatinib – ICLUSIG (CAP)

- Evaluation of an RMP in the context of a variation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002695/II/0005/G, *Orphan*
Procedure scope: Update of SmPC section 4.5 to reflect the results from study AP24534-12-107 (open-label, non-randomized, inpatient/outpatient clinical study to assess the effect of rifampicin on the Pharmacokinetics of ponatinib, when administered concomitantly in healthy subjects; Update of SmPC sections 4.4, 4.5, 5.2 to reflect the results from study AP24534-12-108 (clinical study to evaluate the effect of multiple doses of lansoprazole on the pharmacokinetics of ponatinib when administered concomitantly to healthy subjects; Update of SmPC sections 4.2, 4.4, 4.5 and 5.2 to reflect the results from study AP24534-12- 109 (evaluation of pharmacokinetics and safety of ponatinib in patients with chronic hepatic impairment and matched healthy subjects; Update of SmPC sections 4.5 to reflect the results from study ARI-001A (simcyp physiologically-based PBPK modeling to determine the impact of different ketoconazole dosing regimens on the pharmacokinetics of ponatinib due to CYP3A4 inhibition); Update of SmPC section 5.2 to reflect the results from study ARP350 (in vitro study to determine whether co-administered drugs that are highly bound to human plasma proteins can displace ponatinib from its binding sites). Submission of the results of study ARP395 (a follow up study in which plasma samples from post 24 hr collections were analyzed to determine metabolite profile); Submission of the results of study XT133050 (study on the potential for ponatinib to induce cytochrome P450 (CYP) enzymes in cultured human hepatocytes).In addition, the RMP is updated to reflect the data submitted and to reflect changes requested as part of variation EMEA/H/C/002695/II/002
MAH(s): Ariad Pharma Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

5.2.21. Saquinavir – INVIRASE (CAP)

- Evaluation of an RMP in the context of a variation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Harald Herkner (AT)

Administrative details:
Procedure number(s): EMEA/H/C/000113/II/0104
Procedure scope: Update of SmPC sections 5.1 and 5.2 with results from phase I clinical study investigating the effect of modified saquinavir/ritonavir dosing regimen (500 mg saquinavir/100 mg ritonavir bid) on the QTc interval, pharmacokinetics and antiviral activity in HIV-1 infected patients. This study was conducted as a post authorisation measure required in the RMP and Annex II of the MA. In line with results of the study, recommendations for on treatment ECG are amended in SmPC section 4.4. In addition, Annex II is updated to delete the requirement to conduct this study
MAH(s): Roche Registration Ltd
Documents:
For adoption: PRAC RMP AR, PRAC RMP Assessment overview and Advice

RMP evaluated in the context of a PSUR procedure

See Aflibercept (ZALTRAP) under 6.1.1. , Axitinib (INLYTA) under 6.1.4. , Brentuximab vedotin (ADCETRIS) under 6.1.6. , Emtricitabine, rilpivirine, tenofovir disoproxil (EVIPLERA) under 6.1.12. , Nalmefene (SELINCRO) under 6.1.18. , Natalizumab (TYSABRI) under 6.1.19. , Nonacog alfa (BENEFIX) under 6.1.21. , Orlistat (ALLI) under 6.1.22. , Prasugrel (EFIENT) under 6.1.25.

RMP evaluated in the context of PASS results

See Human rotavirus (ROTARIX) under 7.4.5.

RMP in the context of a renewal of the marketing authorisation, conditional renewal or annual reassessment

See Characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins (CHONDROCELECT) under 8.1.2. , Everolimus (AFINITOR) under 8.1.7. , Saxagliptin (ONGLYZA) under 8.1.11. , Tolcapone (TASMAR) under 8.1.14. , Vinflunine (JAVLOR) under 8.1.16.

RMP in the context of a stand-alone RMP procedure

None

6. Periodic Safety Update Reports (PSURs)

6.1. Evaluation of PSUR procedures[3]

6.1.1. **Aflibercept – ZALTRAP** (CAP)

- Evaluation of a PSUR procedure

***Status:** for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

[3] Where a regulatory action is recommended (variation, suspension or revocation of the terms of Marketing Authorisation(s)), the assessment report and PRAC recommendation are transmitted to the CHMP for adoption of an opinion. Where PRAC recommends the maintenance of the terms of the marketing authorisation(s), the procedure finishes at the PRAC level

Administrative details:
Procedure number(s): EMEA/H/C/002532/PSU 006 (with RMP version 2.0)
MAH(s): Sanofi-Aventis Groupe
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.2. Agalsidase beta – **FABRAZYME** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/000370/PSU 061
MAH(s): Genzyme Europe BV
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.3. Asenapine – **SYCREST** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/001177/PSU 009
MAH(s): N.V. Organon
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.4. Axitinib – **INLYTA** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Doris Stenver (DK)

Administrative details:
Procedure number(s): EMEA/H/C/002406/PSU 008 (with RMP version 8.0)
MAH(s): Pfizer Limited
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.5. Azilsartan medoxomil – **EDARBI** (CAP), **IPREZIV** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

Administrative details:
Procedure number(s): EMEA/H/C/002293/PSU 005, EMEA/H/C/002517/PSU 005
MAH(s): Takeda Global Research and Development Centre (Europe) Ltd.
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.6. Brentuximab vedotin – ADCETRIS (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/002455/PSU 017 (with RMP version 3.0)
MAH(s): Takeda Pharma A/S
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.7. Busulfan – BUSILVEX (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

Administrative details:
Procedure number(s): EMEA/H/C/000472/PSU 028
MAH(s): Pierre Fabre Médicament
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.8. Catridecacog – NOVOTHIRTEEN (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

Administrative details:
Procedure number(s): EMEA/H/C/002284/PSU 010
MAH(s): Novo Nordisk A/S
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.9. Colistimethate sodium – COLOBREATHE (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/001225/PSU 003
MAH(s): Forest Laboratories UK Limited
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.10. Crizotinib – XALKORI (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

Administrative details:
Procedure number(s): EMEA/H/C/002489/PSU 019
MAH(s): Pfizer Limited
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.11. Dronedarone – MULTAQ (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

Administrative details:
Procedure number(s): EMEA/H/C/001043/PSU 034
MAH(s): sanofi-aventis groupe
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.12. Emtricitabine, rilpivirine, tenofovir disoproxil – EVIPLERA (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/002312/PSU 017 (with RMP version 6.0)
MAH(s): Gilead Sciences International Ltd
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.13. Human coagulation factor IX – NONAFACT (CAP), NAPs

- Evaluation of a PSUSA[4] procedure

[4] PSUR single assessment, referring to CAP, NAP

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/PSUSA/00001617/201307
MAH(s): Sanquin, Central Laboratory of the Netherlands Red Cross (CLB) (Nonafact), Aimafix Ixed (Kedrion SPA), Instituto Grifols (Alphanine), CSL Behring GmbH (Berinin P, Mononine), LFB Biomedicaments (Betafact), Instituto Grifols SA (Factor IX Grifols 50 UI/ml, Novix), Biotest Pharma GmbH (Haemonine), Octapharma (Octanine F)
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.14. Human protein C – CEPROTIN (CAP), NAP

- Evaluation of a PSUSA[5] procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

Administrative details:
Procedure number(s): E EMEA/H/C/PSUSA/00002563/201307
MAH(s): Baxter AG, LFB Biomedicaments (Protexel)
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.15. Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) – OPTAFLU (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/000758/PSU 047
MAH(s): Novartis Vaccines and Diagnostics GmbH
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.16. Loxapine – ADASUVE (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/002400/PSU 005
MAH(s): Alexza UK Ltd.
Documents:

[5] PSUR single assessment, referring to CAP, NAP

For adoption: PRAC PSUR AR, PRAC recommendation

6.1.17. **Moroctocog alfa – REFACTO AF** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Doris Stenver (DK)

Administrative details:
Procedure number(s): EMEA/H/C/000232/PSU 140
MAH(s): Pfizer Limited
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.18. **Nalmefene – SELINCRO** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

Administrative details:
Procedure number(s): EMEA/H/C/002583/PSU 005 (with RMP version 2.0)
MAH(s): H. Lundbeck A/S
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.19. **Natalizumab – TYSABRI** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

Administrative details:
Procedure number(s): EMEA/H/C/000603/PSU 058 (with RMP version 16.0)
MAH(s): Biogen Idec Ltd
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.20. **Nomegestrol, estradiol – IOA** (CAP), **ZOELY** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

Administrative details:
Procedure number(s): EMEA/H/C/002068/PSU 007, EMEA/H/C/001213/PSU 007
MAH(s): Merck Sharp & Dohme Limited (Ioa), Theramex S.r.l. (Zoely)

Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.21. **Nonacog alfa – BENEFIX** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

Administrative details:
Procedure number(s): EMEA/H/C/000139/PSU 142 (with RMP version 8.0)
MAH(s): Pfizer Limited
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.22. **Orlistat – ALLI** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000854/PSU 024 (with RMP version 13)
MAH(s): Glaxo Group Ltd
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.23. **Peginterferon alfa-2b – PEGINTRON** (CAP), **VIRAFERONPEG** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

Administrative details:
Procedure number(s): EMEA/H/C/000280/PSU 084 (PegIntron), EMEA/H/C/000329/PSU 081 (ViraferonPeg)
MAH(s): Merck Sharp & Dohme Limited
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.24. **Pioglitazone – ACTOS** (CAP), **GLUSTIN** (CAP), NAP
Pioglitazone, glimepiride – TANDEMACT (CAP)
Pioglitazone, metformin – COMPETACT (CAP), **GLUBRAVA** (CAP)

- Evaluation of a PSUSA[6] procedure

[6] PSUR single assessment, referring to CAP, NAP

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Almath Spooner (IE)

Administrative details:
Procedure number(s): EMEA/H/C/PSUSA/00002417/201307
MAH(s): Takeda Pharma A/S (Actos, Competact, Glubrava, Glustin, Tandemact), Cinfa Portugal (Pioglitazona Cinfa), Generis Farmaceutica (Pioglitazona Generis), Germed Farmaceutica, lda (Pioglitazona Germed), Torrent Pharma SRL (Pioglitazone Torrent), Heumann Pharma GmbH&Co Generica (Pioglitazone Torrent IT), Torrent Pharma GmbH (Pioglitazone Torrent NL), Torrent Pharma SRL (Pioglitazono Torrent LT), Terix Labs ltd (Zatrip)
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.25. Prasugrel – EFIENT (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Doris Stenver (DK)

Administrative details:
Procedure number(s): EMEA/H/C/000984/PSU 032 (with RMP version 9.0)
MAH(s): Eli Lilly Nederland B.V.
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.26. Romiplostim – NPLATE (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

Administrative details:
Procedure number(s): EMEA/H/C/000942/PSU 031
MAH(s): Amgen Europe B.V.
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.27. Ruxolitinib – JAKAVI (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002464/PSU 009
MAH(s): Novartis Europharm Ltd
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.28. Telavancin – VIBATIV (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/001240/PSU 012
MAH(s): Clinigen Healthcare Ltd
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.29. Telbivudine – SEBIVO (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

Administrative details:
Procedure number(s): EMEA/H/C/000713/PSU 063
MAH(s): Novartis Europharm Ltd
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.30. Tocofersolan – VEDROP (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000920/PSU 012
MAH(s): Orphan Europe S.A.R.L.
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.31. Ulipristal – ESMYA (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002041/PSU 014
MAH(s): Gedeon Richter
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.32. Vemurafenib – ZELBORAF (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002409/PSU 028
MAH(s): Roche Registration Ltd
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.1.33. Vismodegib – ERIVEDGE (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002602/PSU 015
MAH(s): Roche Registration Ltd
Documents:
For adoption: PRAC PSUR AR, PRAC recommendation

6.2. Follow-up to PSUR procedures[7]

6.2.1. Degarelix – FIRMAGON (CAP)

- Evaluation of a follow-up to a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

Administrative details:
Procedure number(s): EMEA/H/C/000986/LEG 035
Procedure scope: Evaluation of MAH's response to PSUR#7 as adopted at PRAC/CHMP in September 2013
MAH(s): Ferring Pharmaceuticals A/S
Documents:
For adoption: Updated PRAC Rap AR

6.2.2. Voriconazole – VFEND (CAP)

- Evaluation of a follow-up to a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

[7] Follow up as per the conclusions of the previous PSUR procedure, assessed outside next PSUR procedure

Administrative details:
Procedure number(s): EMEA/H/C/000387/LEG 085.1
Procedure scope: Evaluation of MAH's response to PSUR#13 as adopted at PRAC in October 2013
MAH(s): Pfizer Limited
Documents:
For adoption: Updated PRAC Rap AR

7. Post-authorisation Safety Studies (PASS)

7.1. Protocols of PASS imposed in the marketing authorisation(s)[8]

7.1.1. Brentuximab vedotin - ADCETRIS (CAP)

- Evaluation of an imposed PASS protocol

Status: *for discussion and agreement of PRAC letter of endorsement/objection/notification*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/002455/SOB/008
Procedure scope: Evaluation of PASS protocol (MA25101) for an observational cohort study of the safety of brentuximab vedotin in the treatment of relapsed or refractory CD30+ Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma
MAH(s): Takeda Pharma A/S
Documents:
For adoption: PRAC AR, Letter of endorsement/objection/notification that study is a clinical trial

7.1.2. Defibrotide - DEFITELIO (CAP)

- Evaluation of an imposed PASS protocol

Status: *for discussion and agreement of PRAC letter of endorsement/objection/notification*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002393/SOB 001
Procedure scope: Evaluation of the MAH's responses to a LoQ for PASS protocol - DF VOD-2012-03-REG (patient registry to investigate the long term safety, health outcomes and patters of utilisation of deifibrotide during normal use)
MAH(s): Gentium S.p.A.
Documents:
For adoption: PRAC AR, Letter of endorsement/objection/notification that study is a clinical trial

7.2. Protocols of PASS non-imposed in the marketing authorisation(s)[9]

7.2.1. Colistimethate sodium – COLOBREATHE (CAP)

- Evaluation of a PASS protocol

[8] In accordance with Article 107n of Directive 2001/83/EC
[9] In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/001225/MEA/008.1
Procedure scope: Evaluation of the MAH's responses to MEA-008 RSI as adopted in July 2013: systemic absorption study in cystic fibrosis patients. Revised protocol for a long term observational safety study for Colobreathe in cystic fibrosis patients using cystic fibrosis registries
MAH(s): Forest Laboratories UK
Documents:
For adoption: PRAC advice

7.2.2. Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil – STRIBILD (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/002574/MEA/002.1
Procedure scope: Evaluation of the MAH's responses to MEA 002 PASS protocol as adopted in October 2013: prospective, observational drug utilisation study of Stribild in Adults with HIV-1 Infection (GS-EU-236-0141)
MAH(s): Gilead Sciences International Ltd
Documents:
For adoption: PRAC advice

7.2.3. Fenofibrate, pravastatin – PRAVAFENIX (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

Administrative details:
Procedure number(s): EMEA/H/C/001243/MEA/007.3
Procedure scope: Evaluation of an observational study protocol: European, observational, three-year cohort study on the safety of the fixed-dose combination pravastatin 40 mg/fenofibrate 160 mg (Pravafenix) in real clinical practice (FENOPRA-IV-14-1)
MAH(s): Laboratoires SMB S.A.
Documents:
For adoption: PRAC advice

7.2.4. Insulin degludec – TRESIBA (CAP)

- Evaluation of a PASS protocol

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002498/MEA/001.1
Procedure scope: Evaluation of updated protocol for colour-blindness usability study PDS290-UT117-2013 also including the MAH's response to MEA 001 as adopted by PRAC/CHMP in October 2013
MAH(s): Novo Nordisk A/S
Documents:
For adoption: PRAC advice

7.3. Results of PASS imposed in the marketing authorisation(s)[10]

None

7.4. Results of PASS non-imposed in the marketing authorisation(s)[11]

7.4.1. Agomelatine – **THYMANAX** (CAP), **VALDOXAN** (CAP)

- Evaluation of PASS results

Status*: for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

Administrative details:
Procedure number(s): EMEA/H/C/000916/II/0020, EMEA/H/C/000915/II/0022 (without RMP)
Procedure scope: Evaluation of results from the prescription survey on the knowledge of prescribing conditions of Valdoxan/Thymanax (agomelatine) by psychiatrists and general practitioners in four European countries as requested by the CHMP (MEA 005)
MAH(s): Servier (Ireland) Industries, Les Laboratoires Servier
Documents:
For adoption: PRAC AR

7.4.2. Buprenorphine, naloxone – **SUBOXONE** (CAP)

- Evaluation of PASS results

Status*: for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

Administrative details:
Procedure number(s): EMEA/H/C/000697/II/0020 (without RMP)
Procedure scope: Evaluation of final PASS study report (monitoring pregnancy outcomes among pregnant opioid dependent women using medical registries)
MAH(s): RB Pharmaceuticals Ltd.
Documents:
For adoption: PRAC AR

7.4.3. Buprenorphine, naloxone – **SUBOXONE** (CAP)

- Evaluation of PASS results

[10] In accordance with Article 107p-q of Directive 2001/83/EC
[11] In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013

***Status**: for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

Administrative details:
Procedure number(s): EMEA/H/C/000697/II/0021 (without RMP)
Procedure scope: Evaluation of PASS study PEUS002 (surveillance of hepatic events and other serious adverse events in the UK in Suboxone users in comparison to Subutex and methadone users)
MAH(s): RB Pharmaceuticals Ltd.
Documents:
For adoption: PRAC AR

7.4.4. Buprenorphine, naloxone – SUBOXONE (CAP)

- Evaluation of PASS results

***Status**: for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

Administrative details:
Procedure number(s): EMEA/H/C/000697/II/0022 (without RMP)
Procedure scope: Evaluation of final PASS study report PEUS003 (assessment of fatal overdose in Sweden and Denmark among buprenorphine, methadone and heroin users)
MAH(s): RB Pharmaceuticals Ltd.
Documents:
For adoption: PRAC AR

7.4.5. Human rotavirus – ROTARIX (CAP)

- Evaluation of PASS results

***Status**: for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Jean-Michel Dogné (BE)

Administrative details:
Procedure number(s): EMEA/H/C/000639/II/0062 (with RMP)
Procedure scope: Evaluation of final report of genetic stability study EPI-ROTA-014 VS BE – 112560 that addresses the post-approval measure ME2 005.2 in which the MAH commits to monitor for the potential occurrence of genetic drifts and shifts in the vaccine strain in post-marketing settings
MAH(s): GlaxoSmithKline Biologicals S.A.
Documents:
For adoption: PRAC AR

7.4.6. Palivizumab – SYNAGIS (CAP)

- Evaluation of PASS results

***Status**: for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Line Michan (DK)

Administrative details:
Procedure number(s): EMEA/H/C/000257/II/0098 (without RMP)

Procedure scope: Evaluation of final study report for study A11-632 (observational study carried out to assess the risk of autoimmune and allergic diseases in high risk children exposed to palivizumab, in fulfilment of the post authorisation measure (REC) FU2 032.4)
MAH(s): AbbVie Ltd.
Documents:
For adoption: PRAC AR

7.4.7. Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted) – **PANDEMRIX** (CAP)

- Evaluation of PASS results

Status*: for discussion and adoption of PRAC Assessment Report*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000832/II/0068 (without RMP)
Procedure scope: Evaluation of data from the test-negative case-control analysis of a retrospective epidemiological study conducted in Quebec, Canada to evaluate the risk of narcolepsy associated with vaccination with Arepanrix and to follow-up cases to assess any atypical or differential clinical course and prognosis in any vaccinated vs. non-vaccinated subjects
MAH(s): GlaxoSmithKline Biologicals
Documents:
For adoption: PRAC AR

7.5. Interim results of imposed and non-imposed PASS and results of non-imposed PASS submitted before the entry into force of the revised variations regulation[12]

7.5.1. Apixaban – **ELIQUIS** (CAP)

- Evaluation of interim PASS results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

Administrative details:
Procedure number(s): EMEA/H/C/002148/MEA 012.2
Procedure scope: Evaluation of the first interim report for the following drug utilisation studies (DUS) for apixaban: study of the utilisation pattern in Sweden and study of the utilisation pattern in the Netherlands
MAH(s): Bristol-Myers Squibb / Pfizer EEIG
Documents:
For adoption: PRAC advice

8. Renewals of the Marketing Authorisation, Conditional Renewals and Annual Reassessments

8.1.1. Certolizumab pegol – **CIMZIA** (CAP)

- PRAC consultation on a renewal of the marketing authorisation

[12] In line with the revised variations regulation for any submission before 4 August 2013

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/001037/R/0040 (without RMP)
MAH(s): UCB Pharma SA
Documents:
For adoption: PRAC advice

8.1.2. Characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins – CHONDROCELECT (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

Administrative details:
Procedure number(s): EMEA/H/C/000878/R/0009 (with RMP version 9)
MAH(s): TiGenix NV
Documents:
For adoption: PRAC advice

8.1.3. Clopidogrel – CLOPIDOGREL DURA (CAP), CLOPIDOGREL MYLAN (CAP)

- PRAC consultation on renewals of the marketing authorisations

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Margarida Guimarães (PT)

Administrative details:
Procedure number(s): EMEA/H/C/001132/R/0017 (without RMP), EMEA/H/C/001134/R/0027 (without RMP)
MAH(s): Mylan dura GmbH (Clopidogrel Dura), Mylan S.A.S. (Clopidogrel Mylan)
Documents:
For adoption: PRAC advice

8.1.4. Clopidogrel – CLOPIDOGREL KRKA (CAP), CLOPIDOGREL KRKA D.D. (CAP), ZYLAGREN (CAP), ZYLLT (CAP)

- PRAC consultation on renewals of the marketing authorisations

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Margarida Guimarães (PT)

Administrative details:
Procedure number(s): EMEA/H/C/001056/R/0022 (without RMP) (Clopidogrel Krka), EMEA/H/C/001137/R/0018 (without RMP) (Clopidogrel Krka D.D.), EMEA/H/C/001138/R/0013 (without RMP) (Zylagren), EMEA/H/C/001058/R/0016 (without RMP) (Zyllt)
MAH(s): Krka d.d. Novo Mesto

Documents:
For adoption: PRAC advice

8.1.5. Clopidogrel – CLOPIDOGREL TAD (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Margarida Guimarães (PT)

Administrative details:
Procedure number(s): EMEA/H/C/001136/R/0022 (without RMP)
MAH(s): TAD Pharma GmbH
Documents:
For adoption: PRAC advice

8.1.6. Clopidogrel – CLOPIDOGREL TEVA (CAP)

- PRAC consultation on renewals of the marketing authorisations

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Margarida Guimarães (PT)

Administrative details:
Procedure number(s): EMEA/H/C/001053/R/0029 (without RMP)
MAH(s): Teva Pharma B.V.
Documents:
For adoption: PRAC advice

8.1.7. Everolimus – AFINITOR (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

Administrative details:
Procedure number(s): EMEA/H/C/001038/R/0036 (with RMP)
MAH(s): Novartis Europharm Ltd
Documents:
For adoption: PRAC advice

8.1.8. Fampidrine – FAMPYRA (CAP)

- PRAC consultation on a conditional renewal of the marketing authorisation

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

Administrative details:
Procedure number(s): EMEA/H/C/002097/R/0014 (without RMP)
MAH(s): Biogen Idec Ltd.
Documents:
For adoption: PRAC advice

8.1.9. Pandemic influenza vaccine (H5N1, whole virion, vero cell derived, inactivated) – PANDEMIC INFLUENZA VACCINE H5N1 BAXTER (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

Administrative details:
Procedure number(s): EMEA/H/C/001200/R/0016 (without RMP)
MAH(s): Baxter AG
Documents:
For adoption: PRAC advice

8.1.10. Raltegravir – ISENTRESS (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000860/R/0045 (without RMP)
MAH(s): Merck Sharp & Dohme Limited
Documents:
For adoption: PRAC advice

8.1.11. Saxagliptin – ONGLYZA (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

Administrative details:
Procedure number(s): EMEA/H/C/001039/R/0023 (with RMP version 4)
MAH(s): Bristol-Myers Squibb/AstraZeneca EEIG
Documents:
For adoption: PRAC advice

8.1.12. Sildenafil – VIZARSIN (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

Administrative details:
Procedure number(s): EMEA/H/C/001076/R/0018 (without RMP)
MAH(s): Krka d.d. Novo Mesto
Documents:
For adoption: PRAC advice

8.1.13. Strontium ranelate – OSSEOR (CAP), PROTELOS (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/000561/R/0036 (without RMP) (Osseor), EMEA/H/C/000560/R/0041 (without RMP) (Protelos)
MAH(s): Les Laboratoires Servier
Documents:
For adoption: PRAC advice

8.1.14. Tolcapone – TASMAR (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Almath Spooner (IE)

Administrative details:
Procedure number(s): EMEA/H/C/000132/R/0047 (with RMP version 6)
MAH(s): Meda AB
Documents:
For adoption: PRAC advice

8.1.15. Topotecan – TOPOTECAN TEVA (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/001071/R/0007 (without RMP)
MAH(s): Teva Pharma B.V.
Documents:
For adoption: PRAC advice

8.1.16. Vinflunine – JAVLOR (CAP)

- PRAC consultation on a renewal of the marketing authorisation

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000983/R/0014 (with RMP version 13)
MAH(s): Pierre Fabre Médicament
Documents:
For adoption: PRAC advice

8.1.17. Vismodegib – ERIVEDGE (CAP)

- PRAC consultation on a conditional renewal of the marketing authorisation

***Status:** for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

Administrative details:
Procedure number(s): EMEA/H/C/002602/R/0006 (without RMP)
MAH(s): Roche Registration Ltd
Documents:
For adoption: PRAC advice

9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections

None

9.2. On-going or concluded pharmacovigilance inspection

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

10. Other Safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation (MA)

10.1.1. Measles, mumps, rubella and varicella vaccine – PROQUAD (CAP), M-M RVAXPRO (CAP)

- PRAC consultation on a safety-related variation, upon CHMP request

***Status**: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

Administrative details:
Procedure number(s): EMEA/H/C/WS0492 (without RMP)
Procedure scope: Update of SmPC section 4.8 to include acute disseminated encephalomyelitis (ADEM) based on a review of reports of cases of encephalopathy consistent with ADEM for measles, mumps and rubella virus vaccine live (M-M-R II / M-M-RVaxpro) and measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live (ProQuad)
MAH(s): Sanofi Pasteur MSD, SNC
Documents:
For adoption: PRAC advice

10.1.2. Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted) – PANDEMRIX (CAP)

- PRAC consultation on a safety-related variation, upon CHMP request

Status*: for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Rafe Suvarna (UK)

Administrative details:
Procedure number(s): EMEA/H/C/000832/II/0069
Procedure scope: Restriction of the indication to adults 18 years of age and older in an officially declared pandemic situation caused by A (H1N1)v 2009 virus and to update sections 4.2, 4.4, 4.8 and 5.1 of the SmPC to reflect the totality of the data on the risk of narcolepsy and an updated benefit-risk assessment of Pandemrix, based on the data currently available to the MAH on H1N1 influenza disease burden, effectiveness and safety of Pandemrix and available epidemiology data on narcolepsy
MAH(s): GlaxoSmithKline Biologicals
Documents:
For adoption: PRAC advice

See also under 5.2.17.

10.2. Timing and message content in relation to MS safety announcements

None

10.3. Other requests

None

11. Other Safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

None

11.2. Renewals of the Marketing Authorisation

None

11.3. Other requests

11.3.1. **Antidiabetics** (CAP, NAP)

- PRAC consultation on national review of the safety of insulins in patients with type 2 diabetes mellitus, on Member State's request

Status: *for discussion and agreement of advice to Member States*

Regulatory details:
Lead PRAC member: Julie Williams (UK)

Administrative details:
Procedure scope: UK's review of the safety of insulins used in the treatment of Type 2 diabetic patients
MAH(s): Eli Lilly Nederland B.V. (Humalog, Liprolog) Novo Nordisk A/S (Actrapid, Actraphane, Insulatard, Levemir, Novorapid, Novomix, Tresiba), Sanofi-aventis Deutschland GmbH (Apidra, Insuman, Insulin human Withrop, Lantus), various
Documents:
For adoption: PRAC advice

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

12.1.1. PRAC Rules of Procedure

- Revision of the Rules of Procedure

Status: *for adoption*

12.2. Pharmacovigilance audits and inspections

12.2.1. Pharmacovigilance Systems and their Quality Systems

None

12.2.2. Pharmacovigilance Inspections

12.2.2.1. Union Procedure on Follow-up to Pharmacovigilance Inspections

- Union procedure on the coordination of EU pharmacovigilance inspections
- Union procedure on sharing of pharmacovigilance inspection information

Status*: for discussion*

12.2.3. Pharmacovigilance Audits

None

12.3. Periodic Safety Update Reports & Union Reference Date (EURD) List

12.3.1. Periodic Safety Update Reports

None

12.3.2. PSURs Repository

None

12.3.3. Union Reference Date List

12.3.3.1. Consultation on the draft List, version March 2014

Status: *for discussion and agreement of the list*

12.4. Signal Management

12.4.1. Signal Management

12.4.1.1. Feedback from Signal Management Review Technical (SMART) Working Group

Status: *for information*

12.4.1.2. Update of the Signal Management worksharing list

Status: *for discussion*

12.5. Adverse Drug Reactions reporting and additional reporting

12.5.1. Management and Reporting of Adverse Reactions to Medicinal Products

None

12.5.2. Additional Monitoring

None

12.5.3. List of Product under Additional Monitoring

12.5.3.1. Consultation on the draft List, version March 2014

Status*: for information*

12.6. EudraVigilance Database

12.6.1. Activities related to the confirmation of full functionality

None

12.6.2. Changes to EudraVigilance Database and functional specifications

None

12.7. Risk Management Plans and Effectiveness of risk Minimisations

12.7.1. Risk Management Systems

None

12.7.2. Tools, Educational Materials and Effectiveness Measurement for Risk Minimisation

None

12.8. Post-authorisation Safety Studies

12.8.1. Post-Authorisation Safety Studies

None

12.9. Community Procedures

12.9.1. Referral Procedures for Safety Reasons

None

12.10. Renewals, conditional renewals, annual reassessments

None

12.11. Risk communication and Transparency

12.11.1. Public Participation in Pharmacovigilance

None

12.11.2. Safety Communication

12.11.2.1. Communication on prevention of medication errors

***Status**: for information*

12.11.2.2. Timing of finalisation of PRAC communication – process improvement

***Status**: for information*

12.12. Continuous pharmacovigilance

12.12.1. Continuous Pharmacovigilance, Ongoing Benefit-Risk Evaluation, Regulatory Status and Planning of Public Communication

None

12.12.2. Incident Management

None

12.13. Interaction with EMA Committees and Working Parties

12.13.1. Committees

None

12.13.2. Working Parties

12.13.1. Vaccine Working Party (VWP)

- Draft interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU

Status: *for adoption*

12.13.2. Scientific Advisory Groups (SAG)

12.13.3. Inter-Committee Scientific Advisory Group for Oncology

- Call for nominations

Status: *for discussion*

12.14. Interaction within the EU regulatory network

12.14.1. Pharmacovigilance Audit Facilitation Group (PAFG)

- Standardisation for preparing, performing and reporting pharmacovigilance audits to European Commission

Status*: for discussion*

12.15. Contacts of the PRAC with external parties and interaction of the EMA with interested parties

12.15.1. Guidelines of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)

None

12.15.2. Others

None

13. Any other business

13.1.1. EMA move in 2014 to new building

Status*: for information*